INTERLEUKIN-2 WITH EXVIVO ACTIVATED KILLER-CELLS - THERAPY OF ADVANCED NON-SMALL-CELL LUNG-CANCER

被引:21
作者
BERNSTEIN, ZP
GOLDROSEN, MH
VAICKUS, L
FRIEDMAN, N
WATANABE, H
RAHMAN, R
PARK, J
ARBUCK, SG
SWEENEY, J
VESPER, DS
TAKITA, H
ZEFFREN, J
DENNIN, RA
FOON, KA
机构
[1] ROSWELL PK CANC INST,DEPT SURG,BUFFALO,NY 14263
[2] ROSWELL PK CANC INST,DEPT LAB MED,BUFFALO,NY 14263
[3] ROSWELL PK CANC INST,DEPT RADIOL,BUFFALO,NY 14263
[4] HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110
来源
JOURNAL OF IMMUNOTHERAPY | 1991年 / 10卷 / 05期
关键词
INTERLEUKIN-2; LYMPHOKINE-ACTIVATED KILLER CELLS; NON-SMALL-CELL LUNG CARCINOMA;
D O I
10.1097/00002371-199110000-00012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A phase II study was conducted to examine the efficacy of interleukin-2 (IL-2) with lymphokine-activated killer (LAK) cells as therapy for advanced non-small-cell lung carcinoma (NSCLC). IL-2 was administered at a fixed dose of 6 x 10(6) U/M2 per day as a 24 h continuous intravenous infusion (CIV) with LAK cells. Eleven patients were entered onto this study and six were evaluable. One patient had a near complete response of 18 months duration. Only two patients were able to complete the regimen without dose reduction. This regimen was poorly tolerated with pulmonary toxicity being the major problem. The partial responder was the only patient to undergo more than one course of therapy. IL-2/LAK therapy may have activity in NSCLC and further studies are warranted in this uniformly fatal disease. However, future studies will have to incorporate less toxic IL-2 regimens.
引用
收藏
页码:383 / 387
页数:5
相关论文
共 19 条
[1]   PHASE-I EVALUATION OF RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT DISEASE [J].
ATKINS, MB ;
GOULD, JA ;
ALLEGRETTA, M ;
LI, JJ ;
DEMPSEY, RA ;
RUDDERS, RA ;
PARKINSON, DR ;
REICHLIN, S ;
MIER, JW .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1380-1391
[2]   INTERLEUKIN-2 LYMPHOKINE-ACTIVATED KILLER-CELL THERAPY OF NON-HODGKINS-LYMPHOMA AND HODGKINS-DISEASE [J].
BERNSTEIN, ZP ;
VAICKUS, L ;
FRIEDMAN, N ;
GOLDROSEN, MH ;
WATANABE, H ;
RAHMAN, R ;
ARBUCK, SG ;
SWEENEY, J ;
VESPER, D ;
HENDERSON, ED ;
ZEFFREN, J ;
DENNIN, RA ;
LEVITT, D ;
FOON, KA .
JOURNAL OF IMMUNOTHERAPY, 1991, 10 (02) :141-146
[3]  
BOLT DH, 1988, CANCER RES, V48, P4409
[4]   FUNCTIONAL CONSEQUENCES OF INTERLEUKIN-2 RECEPTOR EXPRESSION ON RESTING HUMAN-LYMPHOCYTES - IDENTIFICATION OF A NOVEL NATURAL-KILLER-CELL SUBSET WITH HIGH-AFFINITY RECEPTORS [J].
CALIGIURI, MA ;
ZMUIDZINAS, A ;
MANLEY, TJ ;
LEVINE, H ;
SMITH, KA ;
RITZ, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (05) :1509-1526
[5]  
DEMPSEY RA, 1982, J IMMUNOL, V129, P2504
[6]   THORACIC RADIOTHERAPY DOES NOT PROLONG SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL-CELL LUNG-CANCER [J].
JOHNSON, DH ;
EINHORN, LH ;
BARTOLUCCI, A ;
BIRCH, R ;
OMURA, G ;
PEREZ, CA ;
GRECO, FA .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (01) :33-38
[7]   CARDIORESPIRATORY EFFECTS OF IMMUNOTHERAPY WITH INTERLEUKIN-2 [J].
LEE, RE ;
LOTZE, MT ;
SKIBBER, JM ;
TUCKER, E ;
BONOW, RO ;
OGNIBENE, FP ;
CARRASQUILLO, JA ;
SHELHAMER, JH ;
PARRILLO, JE ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :7-20
[8]  
MULSHINE JL, 1989, THORACIC ONCOLOGY, P220
[9]   RECOMBINANT INTERLEUKIN-2 BY CONTINUOUS INFUSION AND ADOPTIVE TRANSFER OF RECOMBINANT INTERLEUKIN-2 ACTIVATED CELLS IN PATIENTS WITH ADVANCED CANCER [J].
PACIUCCI, PA ;
HOLLAND, JF ;
GLIDEWELL, O ;
ODCHIMAR, R .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) :869-878
[10]   INTERLEUKIN-2 THERAPY IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - A PHASE-II STUDY [J].
PARKINSON, DR ;
ABRAMS, JS ;
WIERNIK, PH ;
RAYNER, AA ;
MARGOLIN, KA ;
VANECHO, DA ;
SZNOL, M ;
DUTCHER, JP ;
ARONSON, FR ;
DOROSHOW, JH ;
ATKINS, MB ;
HAWKINS, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) :1650-1656